The FDA authorized Bildyos and Bilprevda as biosimilars to Prolia and Xgeva, increasing bone care choices for osteoporosis, most cancers and extra.The U.S....
Regardless of having a excessive chance of recurrence, platinum-resistant ovarian most cancers now has a useful therapy possibility with Elahere (mirvetuximab soravtansine-gynx), an...
In an interview with CURE, Dr. David A. Taub highlighted Prostate Most cancers Consciousness Month by outlining present therapy choices for sufferers with...
